The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - HCA Healthcare
Stock and Other Ownership Interests - Ellipses Pharma
Consulting or Advisory Role - Engitix; iOnctura; Labgenius
 
Research Funding - BeiGene; Bristol-Myers Squibb; Genentech; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Seagen; Taiho Pharmaceutical
Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
 
Markus H. Moehler
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Lilly; Merck Serono; MSD; Pfizer; Roche; SERVIER; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; ESMO; German Cancer Society; Merck Serono; MSD; Roche
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Hendrik-Tobias Arkenau
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Josep Tabernero
Stock and Other Ownership Interests - Oniria Therapeutics
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Marcia Cruz-Correa
No Relationships to Disclose
 
HongWei Wang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Hui Xu
Employment - BeiGene
 
Jiang Li
Employment - BeiGene
 
Silu Yang
Employment - BeiGene
 
Rui-hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; HenRui; Junshi Biosciences; KYM Biosciences; Merck Serono; Roche